JNJ dividend yield: 3.36%. MRK dividend yield: 3.25%. Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
JNJ currently offers a 3.36% yield (4.96/share/year) while MRK offers 3.25% (3.08/share/year). JNJ provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in JNJ vs MRK earn per year?
With $10,000 invested today: JNJ pays approximately $336/year. MRK pays approximately $325/year. With DRIP reinvestment over 10 years, these grow to $828/year (JNJ) and $950/year (MRK).
Does JNJ or MRK pay monthly dividends?
JNJ pays quarterly dividends. MRK pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this JNJ vs MRK comparison by email
Save your analysis + get weekly dividend insights. Free forever.